{
  "_metadata": {
    "version": "2.1",
    "ticker": "ASND",
    "asset_name": "qw_transcon_pth"
  },
  "asset": {
    "name": "QW_TransCon_PTH",
    "company": "Ascendis Pharma A/S",
    "ticker": "ASND",
    "target": "Parathyroid hormone",
    "mechanism": "Once-weekly TransCon prodrug designed to match YORVIPATH exposure over entire week",
    "modality": "TransCon prodrug",
    "partner": null,
    "stage": "Preclinical",
    "one_liner": "Preclinical once-weekly TransCon PTH prodrug designed to match YORVIPATH daily exposure over an entire week for improved convenience in hypoparathyroidism"
  },
  "target": {
    "name": "PTH Receptor (PTH1R)",
    "biology": {
      "simple_explanation": "The PTH receptor mediates parathyroid hormone signaling that controls calcium and phosphate balance. This once-weekly formulation aims to sustain PTH levels equivalent to daily YORVIPATH dosing, reducing injection burden for patients with hypoparathyroidism who are already stable on TransCon PTH therapy."
    }
  },
  "clinical_development": {
    "current_stage": "Preclinical",
    "indications_in_development": [
      "Hypoparathyroidism targeting patients on stable YORVIPATH doses"
    ]
  },
  "trials": [],
  "investment_thesis": [],
  "key_risks": [],
  "upcoming_catalysts": [],
  "_source_pages": [
    7,
    11,
    12
  ],
  "_last_extracted": "2026-02-04T13:33:12.101622"
}